Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma

19 Apr 2020

Abstract excerpt

BACKGROUND: The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that Bromodomain and extraterminal (BET) inhibitors can inhibit MYCN expression and suppress MYCN-amplified neuroblastoma in vivo. Furthermore, alterations within RAS-MAPK (mitogen-activated protein kinase) signaling play significant roles in neuroblastoma initiation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Neuroblastoma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32307821
DOI: 10.1002/pbc.28267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaPMID 32307821Read ↗

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsSemantic proximity Read ↗

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified NeuroblastomaSemantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastomaSemantic proximity Read ↗

Daraxonrasib (RMC-6236) is an effective targeted therapy for <i>RAS</i> -mutant neuroblastomaSemantic proximity Read ↗

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastomaSemantic proximity Read ↗

Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified NeuroblastomaSemantic proximity Read ↗

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in NeuroblastomaSemantic proximity Read ↗

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant gliomaSemantic proximity Read ↗

Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.